Ixinity Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to genetic prevalence of hemophilia b, limitations of plasma-derived factors, advancement in recombinant technology, hospital-based bleeding management, rising diagnosis rates.

The growth in the forecast period can be attributed to adoption of extended half-life therapies, expansion of homecare treatment, increasing hemophilia awareness, supportive rare disease reimbursement, innovation in clotting factor engineering. Major trends in the forecast period include shift toward long-acting factor ix therapies, expansion of prophylactic hemophilia care, personalized bleeding disorder management, growth of home infusion programs, improved recombinant protein purity.

The increasing prevalence of hemophilia is expected to drive the growth of the Ixinity market in the future. Hemophilia is an inherited bleeding disorder in which blood fails to clot properly, leading to excessive bleeding from injuries or spontaneously, often requiring medical intervention. The rise in hemophilia cases is attributed to genetic factors, greater recognition of acquired forms, and advancements in diagnostic practices, allowing for the identification of individuals who were previously undiagnosed. Ixinity is used in the treatment of hemophilia B to prevent and control bleeding episodes. It is a recombinant factor IX therapy that helps address clotting deficiencies in those with hemophilia B. For example, in October 2023, the World Federation of Hemophilia, a non-profit organization based in Canada, estimated that the prevalence of hemophilia is approximately 17.1 per 100,000 males for hemophilia A and 3.8 per 100,000 for hemophilia B, with severe cases being much rarer - 6 per 100,000 for hemophilia A and 1.1 per 100,000 for hemophilia B. This results in an estimated 830,895 patients worldwide, including 282,266 with severe forms. Over 257,146 cases of hemophilia have been identified, including 208,957 cases of hemophilia A and 42,203 cases of hemophilia B, along with more than 100,000 cases of von Willebrand disease. Therefore, the growing prevalence of hemophilia is a key factor driving the expansion of the Ixinity market.

The growing aging population is expected to fuel the expansion of the Ixinity market in the coming years. The aging population refers to the increasing proportion of elderly individuals in a population, driven by declining birth rates and rising life expectancy, which have significant implications for healthcare and social systems. This demographic shift is occurring due to healthcare advancements that extend life expectancy and declining birth rates, leading to a smaller proportion of younger individuals. Ixinity benefits elderly individuals with hemophilia B by managing bleeding risks associated with age-related health issues, helping maintain stable clotting factor IX levels. For instance, according to statistics published in January 2024 by the Population Reference Bureau (PRB), a US-based nonprofit organization, the number of Americans aged 65 and older is expected to rise from 58 million in 2022 to 82 million by 2050 (a 47% increase), with their proportion of the total population growing from 17% to 23%. As a result, the increasing aging population is a key factor driving the growth of the Ixinity market.

In March 2023, XOMA Corporation, a biotechnology company based in the US, acquired the commercial payment and a portion of the milestone rights to IXINITY from Aptevo Therapeutics for an undisclosed amount. This acquisition is in line with XOMA's strategy to establish a steady cash flow and supports its goal of accelerating royalty aggregation. Aptevo Therapeutics Inc., a clinical-stage biotechnology company in the US, focuses on developing immuno-oncology therapies for cancer treatment.

Major companies operating in the ixinity market are Medexus Pharma Inc.

North America was the largest region in the ixinity market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ixinity market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ixinity market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the ixinity market by increasing costs for recombinant protein manufacturing inputs, sterile processing equipment, and cold-chain logistics. Hospitals and hemophilia treatment centers in north america and europe are most affected due to import reliance. Treatment affordability pressures have increased for long-term therapy. However, tariffs are driving domestic biologics manufacturing and improving regional supply security for hemophilia treatments.

The ixinity market research report is one of a series of new reports that provides ixinity market statistics, including ixinity industry global market size, regional shares, competitors with a ixinity market share, detailed ixinity market segments, market trends and opportunities, and any further data you may need to thrive in the ixinity industry. This ixinity market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Ixinity is a recombinant clotting factor IX used to manage hemophilia B, a genetic bleeding disorder. It is designed to substitute the deficient or absent factor IX in patients, aiding in the prevention and control of bleeding episodes. Produced using advanced biotechnology, Ixinity ensures a high level of purity and effectiveness. It is typically administered via intravenous infusion and provides a long-acting solution, which reduces the need for frequent infusions to maintain factor IX levels.

The primary indications for Ixinity include routine prophylaxis, on-demand treatment, and perioperative management. Routine prophylaxis involves scheduled treatments to prevent bleeding episodes in individuals with hemophilia. The patient population includes pediatric and adult patients, as well as high-risk groups, with various end users such as hospitals, clinics, hemophilia treatment centers, and home care settings.

The Ixinity market consists of sales of Ixinity (recombinant coagulation factor IX). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.